Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
05 2021
Historique:
received: 07 11 2020
revised: 16 02 2021
accepted: 17 02 2021
pubmed: 28 2 2021
medline: 21 5 2021
entrez: 27 2 2021
Statut: ppublish

Résumé

To assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. Complete data of 415 patients enrolled in a multi institute, prospective trial (#NCT02803086) treated with radical (31%), adjuvant (33%) and salvage (36%) intent at a median dose to pelvic nodes/lymph-nodal area of 53 Gy were available. The most severe changes between baseline and radiotherapy mid-point/end toxicity assessed by Inflammatory Bowel Disease Questionnaire (only Bowel Domain) were considered (ΔIBDQ). The 25th percentile values of these score variations were set as endpoints. DVHs of bowel loops for patients with/without toxicity were compared for each endpoint, having excluded patients with baseline scores <5 (rate ranging between 2% and 7% according to the endpoint): the resulting best dosimetric predictors were combined with selected clinical parameters through multivariate logistic regression (MVA) to derive predictive models. ΔIBDQ ranged between 0.2-1.5 points considering separately each IBDQ symptom. Only four symptoms (IBDQ1 = frequency, IBDQ5 = diarrhea, IBDQ17 = gas passage, IBDQ24 = urgency) showed a median worsening ≥ 1; DVH predicted the risk of worse symptoms for IBDQ5, IBDQ24 and overall Bowel Domain. At multivariable analysis DVHs (best cut-off: V46Gy ≥80 cc) and baseline scores (Odd-Ratio:0.35-0.65) were independently associated to the three end-points. The resulting models were reliable (H&L test: 0.453-0.956), well calibrated (calibration plot: slope = 0.922-1.069, R Constraining the bowel loops (V46 < 80 cc) may reduce the risk of several moderate intestinal symptoms, with a much greater impact for patients with lower IBDQ baseline scores.

Sections du résumé

BACKGROUND AND PURPOSE
To assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer.
MATERIALS AND METHODS
Complete data of 415 patients enrolled in a multi institute, prospective trial (#NCT02803086) treated with radical (31%), adjuvant (33%) and salvage (36%) intent at a median dose to pelvic nodes/lymph-nodal area of 53 Gy were available. The most severe changes between baseline and radiotherapy mid-point/end toxicity assessed by Inflammatory Bowel Disease Questionnaire (only Bowel Domain) were considered (ΔIBDQ). The 25th percentile values of these score variations were set as endpoints. DVHs of bowel loops for patients with/without toxicity were compared for each endpoint, having excluded patients with baseline scores <5 (rate ranging between 2% and 7% according to the endpoint): the resulting best dosimetric predictors were combined with selected clinical parameters through multivariate logistic regression (MVA) to derive predictive models.
RESULTS
ΔIBDQ ranged between 0.2-1.5 points considering separately each IBDQ symptom. Only four symptoms (IBDQ1 = frequency, IBDQ5 = diarrhea, IBDQ17 = gas passage, IBDQ24 = urgency) showed a median worsening ≥ 1; DVH predicted the risk of worse symptoms for IBDQ5, IBDQ24 and overall Bowel Domain. At multivariable analysis DVHs (best cut-off: V46Gy ≥80 cc) and baseline scores (Odd-Ratio:0.35-0.65) were independently associated to the three end-points. The resulting models were reliable (H&L test: 0.453-0.956), well calibrated (calibration plot: slope = 0.922-1.069, R
CONCLUSION
Constraining the bowel loops (V46 < 80 cc) may reduce the risk of several moderate intestinal symptoms, with a much greater impact for patients with lower IBDQ baseline scores.

Identifiants

pubmed: 33639190
pii: S0167-8140(21)06089-8
doi: 10.1016/j.radonc.2021.02.026
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-82

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Andrea Bresolin (A)

San Raffaele Scientific Institute, Milan, Italy; Fondazione Centro San Raffaele, Milan, Italy.

Adriana Faiella (A)

IRCCS Istituto Nazionale dei Tumori "Regina Elena", Rome, Italy.

Elisabetta Garibaldi (E)

Istituto di Candiolo - FPO-IRCCS, Candiolo, Italy.

Fernando Munoz (F)

Ospedale Regionale Parini-AUSL Valle d'Aosta, Aosta, Italy.

Domenico Cante (D)

Ospedale di Ivrea, Ivrea, Italy.

Vittorio Vavassori (V)

Cliniche Gavazzeni-Humanitas, Bergamo, Italy.

Justina Magdalena Waskiewicz (JM)

Comprensorio Sanitario di Bolzano, Bolzano, Italy.

Giuseppe Girelli (G)

Ospedale degli Infermi, Biella, Italy.

Barbara Avuzzi (B)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Elisa Villa (E)

Cliniche Gavazzeni-Humanitas, Bergamo, Italy.

Alessandro Magli (A)

Azienda Ospedaliero Universitaria S. Maria della Misericordia, Udine, Italy.

Barbara Noris Chiorda (B)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Marco Gatti (M)

Istituto di Candiolo - FPO-IRCCS, Candiolo, Italy.

Letizia Ferella (L)

Ospedale Regionale Parini-AUSL Valle d'Aosta, Aosta, Italy.

Angelo Maggio (A)

Istituto di Candiolo - FPO-IRCCS, Candiolo, Italy.

Valeria Landoni (V)

IRCCS Istituto Nazionale dei Tumori "Regina Elena", Rome, Italy.

Stefania Aimonetto (S)

Ospedale Regionale Parini-AUSL Valle d'Aosta, Aosta, Italy.

Carla Sini (C)

San Raffaele Scientific Institute, Milan, Italy.

Tiziana Rancati (T)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Giuseppe Sanguineti (G)

IRCCS Istituto Nazionale dei Tumori "Regina Elena", Rome, Italy.

Riccardo Valdagni (R)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Nadia Di Muzio (N)

San Raffaele Scientific Institute, Milan, Italy; Dept. of Oncology and Hemato-Oncology, University Vita-Salute San Raffaele, Milan, Italy.

Claudio Fiorino (C)

San Raffaele Scientific Institute, Milan, Italy. Electronic address: fiorino.claudio@hsr.it.

Cesare Cozzarini (C)

San Raffaele Scientific Institute, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH